Last Updated: March 29, 2021

   
     


 
Featured Articles

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

IAS Panel Releases Updated 2020 Guidelines on ART and HIV Prevention 

Infectious Disease Advisor | December 4, 2020

TAG’s 2019 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | July 2019

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
   
News Updates

CANN Celebrates Biden Administration Protecting Medicare Part D

Community Access national Network | March 2021

Certain HIV Meds May Trigger Weight Gain 

WebMD | March 16, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Business Wire | March 15, 2021

Another HIV Tivicay Birth Outcome: Better Infant Survival 

Medscape | MARCH 15, 2021

PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund).

ADAP | MARCH 11, 2021

CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI
NATAP | CROI 2021 March 6-10
CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
NATAP | CROI 2021 March 6-10
CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE
NATAP | CROI 2021 March 6-10
CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS
NATAP | CROI 2021 March 6-10
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10

Revisions to TRIUMEQ and DOVATO labeling

FDA | March 2, 2021

Op-ed: Six Protected Classes and Protecting People with HIV

plus | February 26, 2021

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

ViiV Healthcare | February 24, 2021

Ask the Doctors: New HIV treatment administered monthly 

Lompoc Record | February 18, 2021

FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection

ViiV Healthcare | January 21, 2021

MAT Provides Patients with More Transparency Around Medicine Costs

ADAP Advocacy Association | January 21, 2021

Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).

Tivicay approved in Europe in new dispersible tablet for children with HIV 

pharmaphorum | January 14, 2021

Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries

Infectious Disease Advisor | January 11, 2021

Many health plans now must cover full cost of expensive HIV prevention drugs 

Duluth News Tribune | January 10, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

HIV.gov | December 29, 2021

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

ViiV Healthcare | December 21, 2020

Update to CDC's Treatment for Gonococcal Infections, 2020

CDC | December 18, 2020

Fact Sheet for Recipients and Caregivers: Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older

FDA | December 2020

Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill 

NPR | November 19, 2020

Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications 

Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck | November 16, 2020

Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg

FDA | November 2, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV 

PipelineReview.com | October 17, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV 

PipelineReview.com | October 16, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment 

POZ | October 16, 2020

Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients 

BSA bureau | October 15, 2020

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel

Journal of the American Medical Association | October 14, 2020

Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In 

POZ | October 9, 2020

Dentists, do you know which drugs do not mix with remdesivir?

Dr Bicuspid | October 8, 2020

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified

PipelineReview.com | October 8, 2020

HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function

POZ | October 7, 2020

Injectable HIV therapy should save money if adherence is better than to oral therapies 

aidsmap | October 7, 2020

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial 

PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1

Gilead's Truvada faces Teva generics assault amid Descovy switching campaign 

FiercePharma | October 2, 2020

   

 
       
  2019 Archives 2020 Archives